Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
Luca Gianni(Fondazione Michelangelo), Giuseppe Viale(University of Milan), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Giancarlo Bisagni, Marco Colleoni(European Institute of Oncology), Stefania Zambelli(San Raffaele University of Rome), Pinuccia Valagussa(Fondazione Michelangelo), Simona Barlera, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Claudio Zamagni(Policlinico S.Orsola-Malpighi)
Cited by 7
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k